



Klaria Annual Report 2025

Klaria Annual Report 1 January- 31 December 2025

The year in brief

- Net sales amounted to 9.0 MSEK (2.2 MSEK)
- Other operating income amounted to 0.0 MSEK (0.1 MSEK)
- R&D costs amounted to 28.3 MSEK (22.1 MSEK)
- Profit/loss after tax amounted to -47.1 MSEK (-47.8 MSEK)
- Earnings per share amounted to -0.25 SEK (-0.38 SEK)
- Cash flow from operations amounted to -34.2 MSEK (-11.9 MSEK)
- Shareholder's equity as of December 31, 2025 amounted to -12.0 MSEK (3.3 MSEK)
- Cash and cash equivalents as of December 31, 2025 amounted to 0.3 MSEK (0.6 MSEK)

For more information, visit the Klaria Pharma Holding website klaria.com or contact:

Fredrik Hübinette, Chairman of the Board of Directors

info@[klaria.com](mailto:info@klaria.com)

Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.